Pharma's Almanac: Nice Insight's Content Community

Articles
Expert Interviews
Roundtable
Press Releases
Videos
Thought Leaders

Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing

Pain Therapeutics

Sort By

Nice Insight is the market research division of That’s Nice LLC, the leading marketing agency serving life sciences.

Explore

About Us
Nice Insight
That's Nice

Reach Out Team

Contact Us
Advertise

My Account

Login/Sign up

Site

Privacy Policy
Terms And Conditions

© 2024 PHARMA’S ALMANAC. All rights reserved.

1 / 1

1 / 1

The Next Frontier in Neurological Diagnostics and Therapeutics

Neurology

The Next Frontier in Neurological Diagnostics and Therapeutics

Dave Rosa

NeuroOne

PAO-05-24-CL-02May 30, 2024

Unlocking the Therapeutic Potential of Plant-Inspired Minimum Essential Mixtures

Plant-Inspired Drug Discovery

Unlocking the Therapeutic Potential of Plant-Inspired Minimum Essential Mixtures

Andrea Small-Howard, Ph.D.

Gb Sciences, Inc.

PAO-08-022-CL-01September 06, 2022

Late-Stage Positive Results Reported for Nerve Growth Factor Inhibitor

Clinical Trials

Late-Stage Positive Results Reported for Nerve Growth Factor Inhibitor

Nice Insight

PAO-M02-19-NI-017February 21, 2019

Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

Study Results

Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip

Teva Pharmaceutical Industries Ltd.

PR-M09-18-NI-051September 18, 2018

DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CII

FDA

DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CII

DURECT

PR-M08-18-NI-059August 15, 2018